These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 27349790)

  • 21. Application of data mining approach to identify drug subclasses based on solubility and permeability.
    Gatarić B; Parojčić J
    Biopharm Drug Dispos; 2019 Feb; 40(2):51-61. PubMed ID: 30635908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification.
    Kasim NA; Whitehouse M; Ramachandran C; Bermejo M; Lennernäs H; Hussain AS; Junginger HE; Stavchansky SA; Midha KK; Shah VP; Amidon GL
    Mol Pharm; 2004 Jan; 1(1):85-96. PubMed ID: 15832504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neural Network Models for Predicting Solubility and Metabolism Class of Drugs in the Biopharmaceutics Drug Disposition Classification System (BDDCS).
    Ashrafi A; Teimouri K; Aghazadeh F; Shayanfar A
    Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):1-6. PubMed ID: 37864650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The developability classification system: application of biopharmaceutics concepts to formulation development.
    Butler JM; Dressman JB
    J Pharm Sci; 2010 Dec; 99(12):4940-54. PubMed ID: 20821390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biopharmaceutics classification by high throughput solubility assay and PAMPA.
    Obata K; Sugano K; Machida M; Aso Y
    Drug Dev Ind Pharm; 2004 Feb; 30(2):181-5. PubMed ID: 15089052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system.
    Lindenberg M; Kopp S; Dressman JB
    Eur J Pharm Biopharm; 2004 Sep; 58(2):265-78. PubMed ID: 15296954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Applying Biopharmaceutical Classification System (BCS) Criteria to Predict Oral Absorption of Drugs in Dogs: Challenges and Pitfalls.
    Papich MG; Martinez MN
    AAPS J; 2015 Jul; 17(4):948-64. PubMed ID: 25916691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing multilabel classification methods for provisional biopharmaceutics class prediction.
    Newby D; Freitas AA; Ghafourian T
    Mol Pharm; 2015 Jan; 12(1):87-102. PubMed ID: 25397721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations".
    Buckley ST; Frank KJ; Fricker G; Brandl M
    Eur J Pharm Sci; 2013 Sep; 50(1):8-16. PubMed ID: 23583787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elucidating the role of dose in the biopharmaceutics classification of drugs: the concepts of critical dose, effective in vivo solubility, and dose-dependent BCS.
    Charkoftaki G; Dokoumetzidis A; Valsami G; Macheras P
    Pharm Res; 2012 Nov; 29(11):3188-98. PubMed ID: 22760660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System.
    Benet LZ
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):162-7. PubMed ID: 20002064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
    Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S
    Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Biopharmaceutical classification system--experimental model of the prediction of drug bioavailability].
    Golovenko NIa; Borisiuk IIu
    Biomed Khim; 2008; 54(4):392-407. PubMed ID: 18988456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Very rapid dissolution is not needed to guarantee bioequivalence for biopharmaceutics classification system (BCS) I drugs.
    Kortejärvi H; Shawahna R; Koski A; Malkki J; Ojala K; Yliperttula M
    J Pharm Sci; 2010 Feb; 99(2):621-5. PubMed ID: 19844950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug Disposition Classification Systems in Discovery and Development: A Comparative Review of the BDDCS, ECCS and ECCCS Concepts.
    Camenisch GP
    Pharm Res; 2016 Nov; 33(11):2583-93. PubMed ID: 27439505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simulation-based comparison of Biopharmaceutics Classification System and drug structure.
    Chen T; Wu T; Li N; Jiang Y; Yin H; Wu M
    Pharmazie; 2020 Apr; 75(4):124-130. PubMed ID: 32295687
    [No Abstract]   [Full Text] [Related]  

  • 38. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
    Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
    Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid throughput solubility screening method for BCS class II drugs in animal GI fluids and simulated human GI fluids using a 96-well format.
    Guo J; Elzinga PA; Hageman MJ; Herron JN
    J Pharm Sci; 2008 Apr; 97(4):1427-42. PubMed ID: 17724660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The utility of rat jejunal permeability for biopharmaceutics classification system.
    Zakeri-Milani P; Valizadeh H; Tajerzadeh H; Islambulchilar Z
    Drug Dev Ind Pharm; 2009 Dec; 35(12):1496-502. PubMed ID: 19929209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.